Cancer Communications
indexed by SCI
BMC

doi: 10.1186/s40880-017-0182-y
The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
Young Saing Kim, Chi-Young Jeong, Haa-Na Song, Tae Hyo Kim, Hong Jun Kim, Young-Joon Lee and Soon Chan Hong
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center
[Abstract]
Background
The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection.
Methods
We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection.
Results
A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. However, for patients with stages II and III BTC, chemotherapy significantly improved 5-year OS rate (52.4% vs. 35.6%, P = 0.002) and 3-year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation.
Conclusion
Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection.
Chinese Journal of Cancer 2017, Volume: 36, Issue 5
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


Cite this article

Young Saing Kim, Chi-Young Jeong, Haa-Na Song, Tae Hyo Kim, Hong Jun Kim, Young-Joon Lee and Soon Chan Hong. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer. 2017, 36:9. doi:10.1186/s40880-017-0182-y


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China